MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

AbbVie subsidiary Allergan Aesthetics has agreed to acquire Soliton, which is commercialising a cellulite treatment based on research at University of Texas.

The venture fund, focused on companies out of MIT, Harvard and Rochester, has collected more than $191m on its way to a $325m target.

UChicago once again invested in Kin Insurance, participating in a $63.9m series C round that brought its overall funding to nearly $150m.

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The photonic computing technology spinout of MIT has now pocketed $113m in funding altogether.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

Founded at Imperial Collge London, Sprout three years ago, Sprout.ai has now secured $11m in a series A round led by Octopus Ventures.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.